Keywords: GlaxoSmithKline, Avodart, Prostate cancer risk, Label update

GlaxoSmithKline drops Avodart for prostate cancer risk reduction

Article | 24 March 2011

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it will no longer pursue global approval for the use of Avodart ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in